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Abstract
Angiopoietin-1 (Ang1) signals via the receptor tyrosine kinase Tie2 which exists in complex with the related protein Tie1 at
the endothelial cell surface. Tie1 undergoes regulated ectodomain cleavage in response to phorbol esters, vascular
endothelial growth factor (VEGF) and tumour necrosis factor-a (TNFa). Recently phorbol esters and VEGF were found also to
stimulate ectodomain cleavage of Tie2. Here we investigate for the first time the effects of factors activating ectodomain
cleavage on both Tie1 and Tie2 within the same population of cells, and their impact on angiopoietin signalling. We find
that phorbol ester and VEGF activated Tie1 cleavage within minutes followed by restoration to control levels by 24 h.
However, several hours of PMA and VEGF treatment were needed to elicit a detectable decrease in cellular Tie2, with
complete loss seen at 24 h of PMA treatment. TNFa stimulated Tie1 cleavage, and induced a sustained decrease in cellular
Tie1 over 24 h whilst increasing cellular Tie2. These differential effects of agonists on Tie1 and Tie2 result in dynamic
modulation of the cellular Tie2:Tie1 ratio. To assess the impact of this on Ang1 signalling cells were stimulated with VEGF
and TNFa for differing times and Ang1-induced Tie2 phosphorylation examined. Elevated Tie2:Tie1, in response to acute
VEGF treatment or chronic TNFa, was associated with increased Ang1-activated Tie2 in cells. These data demonstrate
cellular levels of Tie1 and Tie2 are differentially regulated by pathophysiologically relevant agonists resulting in dynamic
control of the cellular Tie2:Tie1 balance and modulation of Ang1 signalling. These findings highlight the importance of
regulation of signalling at the level of the receptor. Such control may be an important adaptation to allow modulation of
cellular signalling responses in systems in which the activating ligand is normally present in excess or where the ligand
provides a constitutive maintenance signal.
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Introduction
The angiopoietins are a family of ligands important for blood
vessel formation and maintenance [1,2]. Four angiopoietins have
been identified, angiopoietin-1 (Ang1) to -4 and all are secreted
glycoproteins of approximately 70 kDa [3]. Ang1 and Ang2 are
the best characterized of these ligands and studies with transgenic
mice demonstrate both are essential for viability and correct
vascular formation [4,5]. Ang1 acts primarily on endothelial cells
to enhance monolayer integrity, suppress apoptosis, stimulate
migration and suppress inflammatory gene expression [1,2]. The
actions of Ang1 in vivo reflect these cellular activities and the ligand
is a potent inhibitor of vascular leakage and inflammation as well
as promoting microvessel survival [1,2]. In addition to roles in
angiogenesis, therefore, Ang1 has key functions in vascular
maintenance. The ligand is expressed at relatively constant rates
by perivascular cells and it acts on underlying endothelium where
it maintains its receptor, Tie2, in a state of activation [6]. This
results in a sustained pro-stabilizing effect on the vasculature,
suppressing vessel leakage and inflammatory activation [1,2].
Ang2 is a context dependent antagonist of Ang1, suppressing
binding of Ang1 to its primary receptor, Tie2, blocking Ang1
signalling and functional effects [7]. Consistent with this
antagonistic activity the phenotype of transgenic mice overex-
pressing Ang2 is similar to Ang1 knockout mice [7].
The primary receptor for angiopoietins, Tie2, is a receptor
tyrosine kinase expressed predominantly on endothelial cells [8].
Binding of Ang1 to Tie2 enhances tyrosine kinase and tyrosine
phosphorylation of the receptor resulting in recruitment of
signalling molecules, including the p85 subunit of phosphatidyli-
nositol-3-kinase PI-3K, A20 binding inhibitor of NFkB-2, Dok-R
and Grb2 [1,2,9]. Downstream signalling pathways activated by
Tie2 include the PI-3K/Akt pathway which has been implicated
in the pro-survival, migratory and anti-inflammatory activities of
Ang1 and Erk1/2 pathways2 [1,2,9]. Tie2 interacts at the cell
surface with the related receptor tyrosine kinase Tie1 [10]. The
extracellular domains of Tie1 and Tie2 are similar in overall
structure, comprising of two immunoglobulin-like domains
followed by three EGF-homology sequences, another immuno-
globulin-like domain and three fibronectin III domains before the
transmembrane sequence [11,12,13,14,15,16]. However, the
amino acid identity between the two receptor ectodomains is only
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angiopoietins [8]. Indeed, Tie1 inhibits Ang1 signalling through
Tie2 [17,18].
Recently it has been reported that the extracellular ligand-
binding domain of Tie2 undergoes proteolytic cleavage
[19,20,21]. Tie2 cleavage has been identified by the observed
decrease in full-length receptor and the discovery of soluble Tie2
fragment of approximately 75–85 kDa in size in conditioned
media from endothelial cells [19]. Cleavage was found to occur
over a period of hours constitutively and was activated by phorbol
esters and vascular endothelial growth factor (VEGF) treatment
[19,20]. Importantly, Tie2 ectodomain cleavage has been shown
to occur also in vivo and a soluble extracellular Tie2 fragment has
been observed in blood from healthy volunteers [19]. Cleavage of
Tie2 inhibits the ability of Ang1 to bind and activate signalling. In
addition, the released soluble Tie2 fragment is to bind and
sequester Ang1 and prevent interaction and signalling by any
remaining full-length receptor in the cell membrane. Soluble Tie2
has been shown to bind both Ang1 and Ang2 and decrease the
observed phosphorylation of Tie2 induced by these ligands in non-
endothelial cells expressing Tie2 receptors [20]. Therefore,
activation of Tie2 cleavage may be an important mechanism by
which Ang1 signalling is regulated by stimuli such as VEGF.
Like Tie2, Tie1 also undergoes regulated ectodomain cleavage
in which the extracellular domain of Tie1 is released by
metalloprotease activity [22,23,24]. This occurs under basal
conditions and is activated by a range of stimuli such as phorbol
esters, VEGF, tumour necrosis factor-a and changes in shear stress
[22,23,24,25]. Released Tie1 ectodomain is present in blood [24].
Activated Tie1 cleavage occurs rapidly over a period of minutes
[17]. Importantly, as Tie1 ectodomain is unable to bind Ang1 the
released extracellular part of this receptor does not suppress Ang1
action. Indeed, in contrast to Tie2 cleavage, loss of Tie1 or Tie1
ectodomain actually enhances Ang1 signalling [17,18]. This
occurs because in the Tie1:Tie2 complexes that exist at the cell
surface the extracellular domain of Tie1 restricts access of Ang1 to
Tie2 and loss of Tie1 ectodomain allows increased Ang1 binding
to Tie2 [17].
Taken together the data on Tie1 and Tie2 cleavage raise
questions about the effects of stimuli such as VEGF on Ang1
action. Induction of Tie1 cleavage by VEGF would be expected to
enhance Ang1 activation of Tie2, and this has indeed been
demonstrated [17]. However as this stimulus activates Tie2
cleavage it would be expected also to suppress Tie2 signalling
[20]. These two opposing actions could be reconciled if they
occurred with different kinetics, with an acute increase in
Tie2:Tie1 ratio due to Tie1 cleavage leading to enhancement of
Ang1 signalling, followed by loss of Tie2 causing a decrease in
Tie2:Tie1 and suppressing Ang1 signalling if the stimulus is
maintained. The published data does suggest Tie1 cleavage occurs
more rapidly than Tie2, however the kinetics of cleavage of both
receptors has not been examined in the same population of cells.
Here for the first time we directly examine activated Tie1 and
Tie2 cleavage in human endothelial cells and the impact of this on
cellular Ang1 signalling. Our data show that cleavage of each
receptor is differentially controlled and that this results in dynamic
regulation of the cellular Tie2:Tie1 by pathophysiologically
relevant factors resulting in modulation of Ang1 signalling.
Results
Kinetics of Tie1 and Tie2 cleavage
Cleavage of both Tie1 and Tie2 has been reported to be
strongly activated by PMA in endothelial cells [19,20,23].
Cleavage of both receptors in the same population of cells
therefore was initially examined in response to PMA. To confirm
that Tie2 cleavage occurred under our experimental conditions
HUVEC were challenged with PMA for 24 hours and conditioned
medium for the cells probed for the presence of Tie2 ectodomain
by immunoblotting. As shown in figure 1A, Tie2 ectodomain was
barely detectable in medium from control cells but was clearly
evident in the medium taken from cells treated with PMA,
consistent with previous data [19,20]. Next we examined the
effects of PMA on cellular levels of Tie1 and Tie2 in the same
populations of HUVEC. To do this HUVEC were incubated in
the absence of PMA or with PMA for increasing time, up to
24 hours, and the levels of each receptor examined in the cells by
immunoblotting. As described previously [23], Tie1 is seen as a
doublet of approximately 145 kDa which corresponds to surface
expressed fully glycosylated receptor and a smaller band of
partially glycosylated receptor destined for the cell surface [22].
PMA activates cleavage of full-length glycosylated Tie1, seen as
loss of the upper band of the doublet; this is clearly evident at 1 h
of PMA treatment and continues over the following 7 h (Fig. 1B,
C). By 24 h of PMA treatment cellular Tie1 levels have recovered
and the receptor is found as full-length, uncleaved Tie1 in the cells.
These data are consistent with previous reports showing similar
levels of Tie1 in HUVEC treated for 24 h with PMA as in
untreated cells [23]. In contrast to this, there was little loss of Tie2
in HUVEC over the initial minutes of PMA treatment but loss of
full-length Tie2 could be clearly seen by 24 hours (Figure 1B, C).
These data show that there is an initial acute drop in levels of full-
length Tie1 in response to PMA whilst Tie2 remains relatively
unchanged, whereas by 24 h Tie1 levels are restored and Tie2 is
clearly diminished (Figure 1C).
VEGF is a key physiological activator of both Tie1 and Tie2
cleavage with similar, though less marked, effects as PMA
[20,22,26]. Therefore we tested whether, like PMA, the effects
of VEGF on cellular Tie1 and Tie2 occurred at early and late time
points respectively. To do this HUVEC were stimulated with a
similar concentration of VEGF as previously described [22,26] for
various times up to 24 hours and cellular Tie1 and Tie2
determined by immunoblotting (Fig. 2A). At 30 min loss of
cellular full-length Tie1 protein is seen and levels are restored at
24 h (Fig. 2A). In contrast, and similar to PMA, levels of cellular
Tie2 after 30 min of VEGF stimulation are similar to control
levels, whereas by 24 h of VEGF stimulation cellular Tie2 is
significantly decreased (Fig. 2A). VEGF therefore increases the
cellular ratio of full-length Tie2:Tie1 acutely but decreases the
ratio chronically.
TNFa is also an important activator of Tie1 cleavage in
endothelial cells [22]. However its effects on Tie2 have not been
described. We therefore examined the effects of TNFa on Tie1
and Tie2 at various times up to 24 h. As shown in figure 2B,
TNFa caused a progressive loss of full-length Tie1 from 30 min
and becoming statistically significant at 4 h. In contrast to PMA
and VEGF, TNFa caused a substantial decrease in cellular Tie1 at
24 h (Fig. 2B). Interestingly, in addition to a decrease in the level
of full-length surface expressed Tie1, the level of the lower
molecular mass partially glycosylated form of Tie1 was also found
to be decreased at 24 h. This form of Tie1 is an intracellular
precursor of full-length Tie1 [23]. The decrease in Tie1 precursor
induced by 24 h of TNFa suggests that at this extended time point
the ligand may decrease Tie1 expression. In the same population
of cells TNFa had no detectable effect on cellular Tie2 levels at
30 min. In addition, this cytokine caused a small, statistically
significant, increase in Tie2 at 24 h (Fig. 2B). This stimulatory
effect of TNFa is consistent with a previous report demonstrating
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PMA and VEGF, therefore, this inflammatory cytokine causes an
increase in cellular Tie2:Tie1 ratio chronically.
The data presented in figure 2B suggest that whilst loss of full-
length Tie1 at early time points likely reflects the ability of this
ligand to stimulate cleavage, as previously reported [22], loss at
24 h may not be due to cleavage but decreased expression.
Ectodomain cleavage of Tie1 results in formation of a 45 kDa cell-
associated fragment of the receptor comprising of transmembrane
and intracellular domains [22–24]. Therefore to test whether
TNFa induces cleavage at 30 min and 24 h cells were treated with
the ligand for the relevant times, followed by cell lysis, blotting and
probing of lysates with an antibody that detects the Tie1
intracellular domain (Fig. 2C). TNFa clearly induces formation
of the 45 kDa intracellular domain fragment at 30 min but not
after 24 h treatment indicating the acute decrease in full-length
Tie1 reflects cleavage whereas 24 h effects are not due to cleavage.
For completeness similar experiments were performed with VEGF
(Fig. 2C) and revealed an increase in Tie1 endodomain at 30 min
but not 24, as expected for the acute stimulation of Tie1 cleavage
induced by VEGF.
We also examined levels of released Tie1 and Tie2 ectodomain
at early (30 min) and late (24 h) time points in cells treated with
VEGF and TNFa. As shown in figure 2D, VEGF stimulated an
increase in soluble Tie1 ectodomain at 30 min of stimulation.
Levels of Tie1 ectodomain in the medium was further elevated at
24 h of VEGF treatment, consistent with Tie1 cleavage occurring
over the first few hours of VEGF treatment (Fig. 2A). Levels of
soluble Tie2 ectodomain in the medium were not detectable after
30 min of VEGF treatment but was clearly seen at 24 h (Fig. 2D),
as expected with the increased time required for VEGF to induce
significant Tie2 cleavage (Fig. 2A, B). Treatment of endothelial
cells with TNFa caused detectable soluble Tie1 ectodomain in the
medium after 30 min and substantial levels at 24 h (Fig. 2D). This
effect of TNFa on release of soluble ectodomain suggests the
ligand activated Tie1 cleavage at 30 min and that this is sustained
over the first few hours of TNFa treatment, as shown in figure 2B.
In the case of Tie2 ectodomain, and consistent with the lack of
effect of TNFa on Tie2 cleavage, released Tie2 ectodomain was
not detected in medium of cells treated acutely (30 min) or
chronically (24 h) with the ligand (Fig. 2D).
Taking the findings on full-length cellular Tie1 and release of
ectodomain together these data indicate that VEGF activates Tie1
cleavage acutely but not chronically, whereas TNFa causes Tie1
cleavage acutely and further loss of Tie1 chronically, via effects nt
involving cleavage. Furthermore, chronic, but not acute, VEGF
treatment stimulates loss of Tie2 whereas chronic TNFa treatment
elevates cellular Tie2. The net result of these ligands therefore is
for VEGF to decrease full-length Tie1:Tie2 ratio acutely and
increase the ratio chronically whereas TNFa causes a clear
decrease in Tie1:Tie2 ratio with increasing time of treatment.
Tie2 Endodomain
The cell-associated fragment of Tie1 remaining after ectodo-
main cleavage encompasses transmembrane and intracellular
domains and is clearly observed as an approximately 45 kDa
protein that accumulates in endothelial cells following activation
with PMA, VEGF and other stimuli [22,24]. We were interested
to determine whether the Tie2 fragment generated after Tie2
ectodomain cleavage could be detected in endothelial cells.
HUVEC were therefore treated for 30 min or 24 h with PMA
before analysis of cell lysates for the Tie1 and Tie2 proteolytic
fragment by immunoblotting with antibodies recognizing the
carboxy-terminus of the intracellular domains (Fig. 3A). As
expected from previous studies the 45 kDa Tie1 fragment is
observed within minutes of treatment of cells with PMA (Fig. 3A).
Consistent with the requirement for more chronic stimulation to
induce appreciable cellular Tie2 cleavage, a 55 kDa Tie2
immunoreactive protein appears in cell lysates following 24 h of
PMA treatment (Fig. 3A). In order to confirm that the 55 kDa
protein was derived from Tie2 we used siRNA to suppress Tie2
expression and examined the appearance of the fragment in
response to 24 h PMA treatment. HUVEC were transfected with
control siRNA or siRNA targeting Tie2 and cultured for 24 h then
treated with PMA for an additional 24 h before cell lysis and
detection of Tie2 by immunoblotting (Fig. 3B). Cells transfected
Figure 1. Kinetics of Tie1 and Tie2 Cleavage. A Tie2 extracellular
domain is released from endothelial cells. HUVEC were untreated or
stimulated with 10 ng/ml PMA for 24 h, as indicated, before collection
of culture medium, removal of cellular material by centrifugation and
immunoprecipitation of Tie2 extracellular domain. Immunoprecipitates
were resolved by SDS/PAGE and released Tie2 extracellular domain
detected by immunoblotting. The position of a 75 kDa molecular mass
marker is indicated. B Time course of the effects of PMA on cellular full-
length Tie1 and Tie2. Endothelial cells were incubated with 10 ng/ml
PMA for the times indicated in minutes or hours (h) before cell lysis and
detection of cellular Tie1 by immunoblotting. To determine levels of
full-length Tie2 in the same cell population, blots were stripped and re-
probed for Tie2. Blots were also re-probed for tubulin. The relative
mobility of mass markers is shown in kDa. C Full-length Tie1 (black
circle) and Tie2 (black triangle) in endothelial cells treated with 10 ng/
ml PMA for different times were determined by immunoblotting in
three independent experiments and quantitated by densitometric
scanning. Data are means and SEM and are presented as arbitrary units
normalized to the levels in untreated cells within each experiment. The
asterisk indicates a statistically significant effect of PMA (P,0.05,
Students ‘t’ test).
doi:10.1371/journal.pone.0029319.g001
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55 kDa protein following 24 h PMA treatment whereas this
protein was still apparent in similarly treated cells transfected with
control siRNA (Fig. 3B). These data, together with the correlation
in kinetics of appearance of the 55 kDa with the loss of full-length
Tie2, plus the immunoreactivity of the 55 kDa protein with an
antibody recognizing the Tie2 intracellular domain, are consistent
with the 55 kDa protein being the cell-associated Tie2 cleavage
product.
As a physiological activator, VEGF induces a more modest Tie2
cleavage than PMA and it was important to test whether this
physiologically relevant stimulus is sufficient to induce appearance
of the Tie2 endodomain. Therefore HUVEC were stimulated for
30 min and 24 h with VEGF before analysis for the presence of
Tie2 endodomain by immunoblotting (Fig. 3C). As with PMA, the
55 kDa Tie2 fragment is not observed at 30 min whereas 24 h
treatment with VEGF results in the appearance of the 55 kDa
Tie2 fragment (Fig. 3C). Probing blots for Tie1 endodomain
revealed an increase in Tie1 cellular Tie1 endodomain after
30 min of VEGF treatment and loss by 24 h, consistent with acute
stimulation of cleavage by VEGF causing increased endodomain
levels, followed by degradation of the newly formed endodomain
[17].
It has previously been shown that once formed by ectodomain
proteolysis Tie1 endodomain is degraded by a two step process
involving release of the intracellular domain from the membrane
tethered transmembrane sequence, by c-secretase activity, fol-
lowed by proteosomal degradation of the 42 kDa intracellular
kinase domain [17]. Consequently, inhibition of c-secretase results
in the accumulation the 45 kDa Tie1 endodomain [17]. A similar
two-step degradation occurs for a number of other receptor
tyrosine kinases undergoing regulated ectodomain cleavage,
including ErbB4 and colony-stimulating factor-1 receptor
[28,29]. It was therefore of interest to determine whether the
Tie2 endodomain is also a substrate for c-secretase-mediated
degradation. To test this HUVEC were incubated in the absence
and presence of the c-secretase inhibitor DAPT (N-[N-(3,5-
Diflurophenacetyl-L-alanyl])-S-phenylglycine t-Butyl-Ester), treat-
ed with or without PMA and Tie1 and Tie2 detected in cell lysates
by immunoblotting. As shown in figure 3D, inclusion of PMA
activated formation of the 45 kDa endodomain fragment of Tie1
at 30 min and the c-secretase inhibitor increased the level of this
endodomain. Interestingly, there is also a clear accumulation of
the Tie1 endodomain fragment in cells incubated with c-secretase
inhibitor for 24 h, presumably reflecting inhibition of degradation
of the endodomain produced at basal rates and induced by PMA
Figure 2. Effects of VEGF and TNFa ´ on Tie1 and Tie2 Cleavage. HUVEC were incubated with VEGF A or TNFa B for times up to 24 h as
indicated before cell lysis and detection of cellular full-length Tie1 by immunoblotting. Blots were stripped and re-probed for full-length Tie2 and
tubulin, as indicated. Full-length Tie1 and Tie2 in endothelial cells treated with VEGF or TNFa at the different times points was determined by
immunoblotting in at least three independent experiments and quantitated by densitometric scanning. Data are means and SEM and presented as
arbitrary units normalized to the levels in untreated cells within each experiment. Asterisks indicate significant effect compared with untreated cells
(p,0.05, Student’s ‘t’test). C VEGF and TNFa stimulate formation of the intracellular Tie1 fragment. HUVEC were incubated with VEGF or TNFa for
30 min or 24 h as indicated before cell lysis and detection of cellular Tie1 endodomain by immunoblotting with an antibody recognizing the Tie1 C-
terminus. Blots were stripped and re-probed for tubulin, as indicated. D VEGF and TNFa stimulate release of Tie1 and Tie2 ectodomain from
endothelial cells. HUVEC were untreated or stimulated with VEGF or TNFa for 30 min or 24 h, as indicated, before collection of culture medium,
removal of cellular material by centrifugation and immunoprecipitation of Tie1 and Tie2 extracellular domains. Immunoprecipitates were resolved by
SDS/PAGE and released extracellular domains detected by immunoblotting. The relative mobility of mass markers is shown in kDa.
doi:10.1371/journal.pone.0029319.g002
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stimulated formation of the 55 kDa Tie2 fragment by 24 h this
was not affected by the presence of c-secretase inhibitor (Fig. 3D).
This suggests that Tie2 endodomain is not a substrate for c-
secretase activity. In further work we examined the effects of c-
secretase on endodomains induced by VEGF and TNFa (Fig. 3E,
F). VEGF stimulates formation of Tie1 endodomain at 30 min
and this was enhanced by c-secretase inhibitor. There was no
increase in Tie1 endodomain in response to 24 h of VEGF
treatment, although, as in the case of the PMA experiments, the
presence of c-secretase inhibitor for 24 h did increase the level of
endodomain seen in the cells, reflecting accumulated endodomain
from acute VEGF treatment. VEGF stimulates formation of Tie2
endodomain at 24 h but not 30 min, and c-secretase inhibitor did
not affect this (Fig. 3E). TNFa stimulated Tie1 endodomain
formation at 30 min and, as with VEGF and PMA, in the
presence of c-secretase inhibitor this was further elevated (Fig. 3F).
After 24 h TNFa treatment there was no elevation of Tie1
endodomain but, again, increased endodomain after 24 h in the
presence of c-secretase inhibitor (Fig. 3F). Consistent with the lack
of effect of TNFa on Tie2 cleavage, TNFa did not stimulate
formation of Tie2 endodomain either in the absence or presence
c-secretase inhibitor (Fig. 3F). Together these data show that
whereas Tie1 endodomain is subject to degradation by c-secretase,
this does not appear to be the case for Tie2 endodomain.
Previously we reported the presence of complexes comprising
full-length Tie2 physically associated with Tie1 endodomain in
endothelial cells treated with VEGF [26]. We were therefore
Figure 3. Detection of Tie2 Cell-Associated Endodomain. A Cells were incubated with PMA for the times indicated in hours before cell lysis
and detection of cellular Tie1 endodomain by immunoblotting with an antibody recognizing Tie1 carboxy-terminus, as indicated. Blots were stripped
and re-probed with an antibody to Tie2 intracellular domain, as indicated. The positions of molecular mass markers in kDa are shown on the left of
the blots. B To confirm the 55 kDa Tie2 immunoreactive fragment is derived from Tie2 endothelial cells were transfected with control siRNA (Scr) or
siRNA recognizing Tie2, as indicated. 24 h post-transfection cells were incubated with or without PMA for 24 h before lysis and detection of Tie2
endodomain by immunoblotting. C VEGF stimulates Tie2 endodomain accumulation at 24 h. Endothelial cells were incubated with VEGF for 0.5 or
24 h before cell lysis and detection of cellular Tie2 intracellular domain. Membranes were stripped and reprobed for Tie1 intracellular domain. D
Effects of c-secretase inhibition on Tie1 and Tie2 endodomains formed in response to PMA. HUVEC were incubated with or without the c -secretase
inhibitor in the absence and presence of PMA for 0.5 or 24 h as indicated. Tie1 endodomain was detected in whole cell lysates by immunoblotting
with an antibody recognizing Tie1 carboxy-terminus and blots were stripped and re-probed with an antibody to Tie2 intracellular domain as
indicated. Effects of c-secretase inhibition on Tie1 and Tie2 endodomains formed in response to VEGF (E) and TNFa (F). HUVEC were incubated with
or without the c -secretase inhibitor in the absence and presence of VEGF or TNFa for 0.5 or 24 h as indicated. Tie1 endodomain was detected in
whole cell lysates by immunoblotting with an antibody recognizing Tie1 carboxy-terminus and blots were stripped and re-probed with an antibody
to Tie2 intracellular domain as indicated. G Tie1 endodomain interacts with full-length Tie2. HUVEC were incubated with VEGF or TNFa for 0.5 or 24 h
as indicated. Cells were lysed and Tie2 immunoprecipitated. Tie1 endodomain co-immunoprecipitating with Tie2 was detected by immunoblotting
with an antibody recognizing Tie1 carboxy-terminus and blots were stripped and re-probed with an antibody to Tie2. The relative mobility of mass
markers is shown in kDa.
doi:10.1371/journal.pone.0029319.g003
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chronically with VEGF as well as acutely and chronically with
TNFa. To do this endothelial cells were treated with VEGF or
TNFa for 30 min or 24 h before lysis and immunoprecipitation of
Tie2. Immunoprecipitates were then probed for the presence of
associated Tie1 endodomain. As shown in figure 3G, Tie2 was
found interacting with Tie1 endodomain after 30 min treatment of
cells with VEGF as well as TNFa. However, such complexes were
not observed in cells treated for 24 h with either VEGF or TNFa,
reflecting the lack of Tie1 endodomain in cells treated with either
ligand for 24 h (Fig. 2C, 3E, F).
Effects of Tie1 on Ang1 signalling
We and others have shown that loss of full-length Tie1 or
cleavage of Tie1 ectodomain enhances Ang1 signalling through
Tie2 [17,18]. In contrast, loss of Tie2 ectodomain would be
expected to suppress Ang1 signalling through Tie2 by two routes,
loss of the ligand-binding domain from the receptor plus
sequestration of Ang1 by released ectodomain. Indeed, Findley
et al have recently reported suppression of Ang1-activation of Tie2
by Tie2 ectodomain released by PMA-induced Tie2 ectodomain
cleavage [20]. We hypothesized, therefore, that stimuli that
activate Tie1 and Tie2 cleavage with differing kinetics, such as
VEGF, would regulate Ang1-induced Tie2 signalling. To test this
HUVEC were subjected to acute and chronic stimulation with
VEGF before addition of Ang1 for 30 min. Cells were then lysed
and levels of Tie2 phosphorylation in cells determined by
immunoblotting lysates with anti-phospho-Tie2. As shown in
figure 4A, VEGF treatment for short periods (30 min) increased
Ang1-induced Tie2 phosphorylation in endothelial cells, consistent
with previous reports [17]. However, after 24 h of VEGF
treatment this enhanced cellular Tie2 signal was decreased as
Tie1 levels were restored and Tie2 cleaved (Fig. 4A). Similar
experiments were also performed to examine the effects of PMA-
induced Tie1 cleavage on Ang1-activation of Tie2 (Fig. 4B). As
with VEGF, treatment of cells with PMA for 30 min caused
cleavage of full-length Tie1 and enhanced Ang1-activated Tie2
phosphorylation, whereas by 24 h of PMA treatment full-length
Tie1 was restored, Tie2 decreased and the elevated Ang1-induced
Tie2 phosphorylation decreased (Fig. 4B).
As shown in figure 3, TNFa induces a chronic depression of
cellular full-length Tie1. This result in an increase in the molecular
ratio of Tie2:Tie1 in cells chronically. These effects would be
predicted to increase Ang1-activated Tie2 at 24 h. To test this,
endothelial cells were activated for 30 min or 24 h with TNFa
before stimulating for 30 min with Ang1 and assessment of Tie2
phosphorylation by immunoblotting. As predicted TNFa caused a
significant increase in the level of Ang1-induced Tie2 phosphor-
ylation in cells at 24 h (Fig. 4C). There was little effect of 30 min
TNFa-treatment on Ang1-activated Tie2 phosphorylation, con-
sistent with the finding that although Tie1 cleavage has been
initiated (Fig. 2D) at 30 min there is still appreciable full-length
Tie1 present in the cells (Fig. 2B, 4C). We also confirmed that loss
of Tie1 enhances Ang1-activation of Tie2 by using an siRNA
approach. In these experiments endothelial cells were transfected
with control siRNA or siRNA targeting Tie1. After 24 h cells were
stimulated with Ang1 and levels of phosphorylated Tie2 examined
by immunoblotting as above. Cells transfected with siRNA
targeting Tie1 showed a loss of the receptor and an enhancement
of Ang1-activated Tie2 phosphorylation (Fig. 4D).
Phosphorylation of Tie2 endodomain
In addition to signalling from full-length Tie2 it is possible that
the Tie2 intracellular domain fragment detected in cells following
ectodomain cleavage could have signalling activity. This could
occur in the absence of Ang1 as a result of loss of the Tie2
regulatory ectodomain. Indeed, some other intracellular kinase
domains released following ectodomain cleavage of full-length
receptor tyrosine kinases, such as ErbB4 and TrkA, appear to be
active as judged by their phosphorylation status [30,31]. To test
this, endothelial cells were treated with phorbol ester for 24 h
before stimulation with Ang1 for 30 min. Lysates were resolved by
SDS/PAGE and probed for activated phosphorylated Tie2
endodomain and total Tie2 endodomain by immunoblotting
(Fig. 5A). As before, Tie2 endodomain was detectable after 24 h of
PMA treatment. However, phosphorylation of the endodomain
was not detectable in untreated cells or following Ang1-activation.
It is possible that Tie2 endodomain is phosphorylated at a low
level that is not detectable by anti-phospho-Tie2 immunoblotting
of whole cell lysates. In order to increase the possibility of detecting
phosphorylation of Tie2 endodomain, therefore, cells were treated
with PMA and Ang1 as before and following lysis Tie2
intracellular domain recovered from cell lysates by immunopre-
cipitation with an antibody recognizing the intracellular domain of
Tie2. The phosphorylation status of the 55 kDa Tie2 fragment
was then examined by anti-phosphotyrosine immunoblotting of
immunoprecipitates (Fig. 5B). The 55 kDa Tie2 fragment present
at 24 h of PMA treatment was found to be tyrosine phosphory-
lated, however Ang1 treatment did not affect phosphorylation
status of the endodomain (Fig. 5B).
As shown in figure 3A, 24 h of VEGF treatment stimulates
formation of Tie2 endodomain. It was of interest therefore to
examine whether this endodomain was phosphorylated. To do this
endothelial cells were treated with VEGF for 24 h before
stimulation with Ang1 for 30 min, followed by cell lysis,
immunoprecipitation of Tie2 and probing the recovered Tie2
endodomain for tyrosine phosphorylation (Fig. 5C). As with PMA,
VEGF stimulated Tie2 endodomain formation at 24 h and this
was tyrosine phosphorylated, though Ang1 treatment did not
enhance its phosphorylation (Fig. 5C).
Discussion
In this study we have examined the effect different physiological
activators have on relative levels of Tie receptors and Ang1
signalling. Our data shows that cleavage of cellular Tie1 and Tie2
are both regulated by VEGF but with different kinetics. This
results in an increase in cellular Tie2:Tie1 ratio early after VEGF
stimulation and a decrease in the ratio at later time points. In
contrast, TNFa differentially affects the receptors by enhancing
Tie1 loss whilst increasing Tie2 levels leading to a progressive
increase in Tie2:Tie1 ratio in cells treated with this ligand.
Furthermore, this modulation of Tie1 and Tie2 by VEGF and
TNFa affects Ang1 signalling, with a decrease in Tie1 relative to
Tie2 enhancing Ang1-induced cellular Tie2 activation [17,18],
and decreased Tie2 suppressing cellular Tie2 activation [20].
The mechanisms responsible for the different time courses of
Tie1 and Tie2 cleavage in response to PMA and VEGF are not
known. However, it is possible that this reflects involvement of
different proteases in cleavage of each of the receptors. Recently
matrix metalloprotease-14 (MMP14) has been implicated in
mediating Tie2 cleavage and the increase in PMA-activated
Tie2 cleavage correlates with induction of increased MMP14
expression [21]. Thus the delay in PMA and VEGF-induced
cleavage of Tie2 may be due to the requirement for induction of
transcription and translation of the protease responsible. Although
the protease mediating Tie1 cleavage has not yet been identified,
the rapid activation of cleavage by PMA and VEGF suggests the
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of expression for it to act on the receptor.
The ability of TNFa to cause a time dependent increase in
Tie2:Tie1 ratio in endothelial cells was found to involve both
effects on Tie1 cleavage and effects on expression of Tie1 and
Tie2. As shown in figure 2, TNFa does stimulate cleavage of Tie1
at early time points. However at 24 h of TNFa-treatment the loss
of Tie1 is not restricted to surface expressed full-length Tie1 but
also seen for the precursor form and is not accompanied by the
presence of Tie1 endodomain, indicating effects on Tie1
expression rather than cleavage at this time point. In contrast,
TNFa failed to induce Tie2 cleavage but rather enhanced
expression of Tie2. The ability of TNFa to stimulate expression
of Tie2 has also been observed by others [27]. It will be of interest
in future studies to examine the mechanisms responsible for
TNFa-induced Tie2 expression and suppression of Tie1. Irre-
spective of the mechanism, the data clearly show TNFa causes a
time dependent increase in cellular Tie2:Tie1 ratio which is
particularly marked at 24 h.
Together the findings of the present study show that the
molecular balance between cellular Tie2:Tie1 is dynamically
regulated by pathophysiologically relevant factors and this balance
influences the ability of Ang1 to signal in endothelial cells. These
findings identify the Tie2:Tie1 ratio as a key determinant of
angiopoietin signalling in endothelial cells. Interestingly, Ang1 is
considered to provide a fairly constant maintenance signal to
endothelial cells, is present bound to extracellular matrix and is
produced by perivascular cells at a relatively constant rate [9]. In
Figure 4. Effects of VEGF, PMA and TNFa ´ on Cellular Tie2 Activation. HUVEC were treated with VEGF A, PMA B or TNFa C for 0, 0.5 or 24 h to
induce Tie1 and Tie2 ectodomain cleavage followed by 200 ng/ml Ang1 for 30 min. Cells were lysed and phosphorylated Tie2 detected by
immunoblotting with anti-phospho-Tie2 (pTie2), blots were stripped and re-probed for Tie1, Tie2 and tubulin. Phosphorylated Tie2 in cells treated
with VEGF, PMA or TNFa for 0, 0.5 or 24 h and activated with Ang1 was detected by immunoblotting in at least three independent experiments and
quantitated by densitometric scanning. Data are means and SEM of phospho-Tie2 normalized to that in Ang1-activated control cells within each
experiment. Asterisks indicates significant increase in Ang1-induced Tie2 phosphorylation (p,0.05, Student’s ‘t’test). D Loss of Tie1 enhances Ang1-
activation of Tie2. HUVEC were transfected with contraol siRNA (C) or siRNA targeting Tie1 (Tie1) as indicated. 24 h post-transfection cells were
activated with Ang1 for 30 min before lysis and detection of phosphorylated Tie2 (pTie2), blots were stripped and re-probed for Tie1 and Tie2. The
relative mobility of mass markers is shown in kDa.
doi:10.1371/journal.pone.0029319.g004
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regulation of Ang1 signalling can occur via the antagonist activity
of Ang2 [3,9], which is dynamically regulated by a range of factors
including hypoxia, VEGF and angiotensin II [32,33]. The present
findings suggest an additional mechanism of controlling Ang1
signalling at the level of the Tie2:Tie1 complex by modification of
the cellular Tie2:Tie1 ratio. The ability of physiological stimuli to
regulate this ratio, in both directions, may be important for
integrating angiopoietin signalling with other signals in the
endothelial microenvironment.
The focus of the present study has been to examine the effects of
VEGF and TNFa on the relative levels of Tie1 and Tie2 within
the same population of endothelial cells and the effects on Ang1
signalling. Clearly it will be important to determine the functional
significance of the effects of VEGF and TNFa on Ang1 signalling
in vivo. A prediction from the cellular findings is that in vivo Ang1
signalling under basal conditions is limited by the responsiveness of
the Tie2 receptor, which is determined by the Tie2:Tie1 ratio in
the cell, to the pool of perivascular Ang1. Furthermore, short-term
increases in local VEGF concentration would enhanced Tie2
responsiveness and increase Ang1 signalling. This would allow the
endothelium to maintain a quiescent state due to the presence of
perivascular Ang1 without requiring maximal signalling through
Tie2 under normal basal conditions whilst having the ability to
enhance this pro-quiescent signal by increasing Tie2 responsive-
ness to Ang1 in the presence of transient increases in VEGF in vivo.
Such a mechanism of local regulation of Tie2 responsiveness by
VEGF would prevent short-term fluctuations in VEGF from
causing vascular destabilization without having to maintain
constant maximal levels of Ang1 signalling in the endothelium.
The endothelium would retain the ability to respond acutely to
VEGF if there was a coincident increase in Ang2. In addition,
chronic VEGF elevation would also be expected to result in vessel
destabilization as the enhancement of Tie2 responsiveness to Ang1
does not occur under conditions of long-term VEGF treatment.
Whilst it is possible to speculate on the functional significance of
the cellular effects in vivo it will be important in future work to test
these hypotheses and examine the significance of the cellular
changes in receptors and signalling in pathophysiological situations
in vivo such as during angiogenesis.
In conclusion this study has shown the levels of intact Tie2 and
Tie1 in endothelial cells are differentially controlled in both the
short- and long-term by factors regulating ectodomain cleavage of
the two receptors. This results in modulation of the molecular
Tie2:Tie1 balance in cells by various stimuli. Furthermore, the
molecular balance between these two receptors determines the
level of Ang1-induced Tie2 activation in the cell. These findings
highlight the importance of regulation of signalling at the level of
the receptor. Such control may be an important adaptation to
allow modulation of cellular signalling responses in systems in
which the activating ligand is normally present in excess or where
the ligand provides a constitutive maintenance signal.
Materials and Methods
Cells
Human umbilical vein endothelial cells (HUVEC) were from
Promocell and were maintained in Medium 199 containing 20%
foetal calf serum, 5 units/ml heparin, and 50 mg/ml endothelial
cell growth supplement. As indicated in Results, cells were treated
with the following concentrations of reagents: PMA, 10 ng/ml
(Merck, Nottingham, UK); VEGF, 100 ng/ml (PeproTech,
London, UK); TNFa, 100 ng/ml (PeproTech, London, UK);
Ang1 200 ng/ml (R&D Systems, Abingdon, UK), unless otherwise
indicated. The c-secretase inhibitor (IX, Merck, Nottingham,UK)
was added prior to addition of the PMA and remained in the
media throughout treatment. Annealed, purified and de-salted
double-stranded siRNA oligonucleotides have been previously
detailed [17] and were obtained from MWG Biotech (London,
UK). For transfection with control scrambled siRNA, siRNA
directed against Tie2 or Tie1, HUVEC were grown to
approximately 80% confluence and then transfected with
100 nM siRNA using Lipofectamine as directed in the manufac-
turer’s protocol 48 h before treatments and cell lysis. All other
reagents were as described previously [34,35].
Immunoprecipitation and Immunoblotting
Cells were lysed with ice-cold lysis buffer (50 mM Tris, pH 7.4,
50 mM NaCl, 1 mM sodium fluoride, 1 mM EGTA, 1 mM
sodium orthovanadate, 1% TritonX-100, complete protease
Figure 5. Phosphorylation of Tie2 Endodomain. A Endothelial
cells were incubated for 24 h in the absence of presence of PMA, as
indicated, before stimulation with Ang1 for 30 min. Cell lysates were
resolved by SDS/PAGE, transferred to nitrocellulose and probed for
phospho-Tie2 (pTie2) and Tie2 as indicated. B Following stimulation
with PMA for 24 h endothelial cells were incubated with or without
Ang1 for 30 min, as indicated. Cells were lysed and Tie2 endodomain
recovered from lysates by immunoprecipitation with an antibody
recognizing Tie2 intracellular domain and phosphorylation of Tie2
endodomain determined by anti-phosphotyrosine immunoblotting.
Blots were stripped and re-probed for Tie2 endodomain. C HUVEC were
treated with VEGF for 24 h, with or without Ang1 for 30 min, as
indicated. Cells were lysed and Tie2 endodomain recovered from lysates
by immunoprecipitation with an antibody recognizing Tie2 intracellular
domain and phosphorylation of Tie2 endodomain determined by anti-
phosphotyrosine immunoblotting. Blots were stripped and re-probed
for Tie2 endodomain. The relative mobility of mass markers is shown in
kDa.
doi:10.1371/journal.pone.0029319.g005
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to remove particulate matter.
For analysis of whole cell lysates, Laemmli sample buffer
containing dithiothreitol, to produce a final concentration of
100 mM, was mixed with cleared lysates and boiled for 5 min before
loading equal amounts of protein onto SDS-PAGEand resolving. For
immunoprecipitates, supernatants cleared of particulate material by
centrifugation at 13,0006g for 5 min were immunoprecipitated by
the addition of 2 mg of the indicated antibody for2–3 h in the
presence of protein-A beads. In some experiments Tie2 and Tie1
extracellular domain was immunoprecipitated from conditioned
medium,inthesecasesmediumwasconditionedfor24 handcleared
by centrifugation beforeimmunoprecipitation as for cell lysates. In all
cases immunoprecipitated proteins were recovered by centrifugation
at 13,0006g for 5 min and washed 3 times with wash buffer (as lysis
buffer but with 0.1% Triton X-100). Proteins were eluted from beads
by the addition of Laemmli sample buffer containing 100 mM
dithiothreitol and boiling for 5 min before SDS-PAGE. For
immunoblotting proteins were transferred to nitrocellulose mem-
braneselectrophoretically and membranes probed with Tie1,Tie2 or
phospho-Tie2 antibodies as appropriate. Blots were stripped and re-
probed with anti-tubulin. Immunoreactive proteins were visualized
with peroxidase-conjugated secondary antibodies and chemilumi-
nescent detection [36], quantification of blots was by densitometric
scanning and scans from each track were normalized against tubulin.
Data Analysis
Bands on Western blots were quantified by densitometric
scanning of films. Graphs were derived from 3 or more
independent experiments and data is plotted as means and
standard error. Statistical analysis was performed using Student’s
‘t’ test and differences between means judged statistically
significant for p,0.05.
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